Zhitong Finance App News, Baiyunshan (600332.SH) issued an announcement. Recently, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (“Tianxin Pharmaceutical”), a holding subsidiary of the company, received the approval and issuance of a “Drug Registration Certificate” for irbesartan hydrochlorothiazide tablets from the State Drug Administration. This drug is used to treat essential hypertension, and this fixed-dose combination is used to treat patients who cannot effectively control blood pressure with irbesartan or hydrochlorothiazide alone. Obtaining a registration certificate for this drug has enriched the variety of Tianxin Pharmaceutical's cardiovascular products and is conducive to enhancing the company's competitiveness in the cardiovascular field market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.